By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Drugs > Bazedoxifene (monograph) > Bazedoxifene / Conjugated Estrogens Dosage
Drugs
https://themeditary.com/dosage-information/bazedoxifene-conjugated-estrogens-dosage-10789.html

Bazedoxifene / Conjugated Estrogens Dosage

Drug Detail:Bazedoxifene (monograph) (Medically reviewed)

Drug Class:

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Postmenopausal Symptoms

Conjugated estrogens 0.45 mg/bazedoxifene 20 mg orally once a day

Comments:

  • The duration of therapy should be for the shortest duration consistent with treatment goals and risks for the individual patient. Patients should be re-evaluated periodically as clinically appropriate to determine if treatment is still needed.
  • When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered in women at significant risk of osteoporosis; non-estrogen therapy should be carefully considered.
  • When use is for the prevention of postmenopausal osteoporosis, women whose calcium and/or vitamin D intake is inadequate should add calcium and vitamin D supplementation to their diet.

Uses: Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.

Usual Adult Dose for Prevention of Osteoporosis

Conjugated estrogens 0.45 mg/bazedoxifene 20 mg orally once a day

Comments:

  • The duration of therapy should be for the shortest duration consistent with treatment goals and risks for the individual patient. Patients should be re-evaluated periodically as clinically appropriate to determine if treatment is still needed.
  • When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered in women at significant risk of osteoporosis; non-estrogen therapy should be carefully considered.
  • When use is for the prevention of postmenopausal osteoporosis, women whose calcium and/or vitamin D intake is inadequate should add calcium and vitamin D supplementation to their diet.

Uses: Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.

Usual Geriatric Dose for Postmenopausal Symptoms

65 to less than 75 years:
Conjugated estrogens 0.45 mg/bazedoxifene 20 mg orally once a day

75 years or older: Not Recommended

Comments:

  • The duration of therapy should be for the shortest duration consistent with treatment goals and risks for the individual patient. Patients should be re-evaluated periodically as clinically appropriate to determine if treatment is still needed.
  • When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered in women at significant risk of osteoporosis; non-estrogen therapy should be carefully considered.
  • When use is for the prevention of postmenopausal osteoporosis, women whose calcium and/or vitamin D intake is inadequate should add calcium and vitamin D supplementation to their diet.

Uses: Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.

Usual Geriatric Dose for Prevention of Osteoporosis

65 to less than 75 years:
Conjugated estrogens 0.45 mg/bazedoxifene 20 mg orally once a day

75 years or older: Not Recommended

Comments:

  • The duration of therapy should be for the shortest duration consistent with treatment goals and risks for the individual patient. Patients should be re-evaluated periodically as clinically appropriate to determine if treatment is still needed.
  • When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered in women at significant risk of osteoporosis; non-estrogen therapy should be carefully considered.
  • When use is for the prevention of postmenopausal osteoporosis, women whose calcium and/or vitamin D intake is inadequate should add calcium and vitamin D supplementation to their diet.

Uses: Treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.

Renal Dose Adjustments

Not recommended

Liver Dose Adjustments

Contraindicated

Precautions

US BOXED WARNINGS: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA:

  • Women taking this combination drug should not take additional estrogen.
  • ENDOMETRIAL CANCER: There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. This drug has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
  • CARDIOVASCULAR DISORDERS: The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (0.625 mg)­ alone, relative to placebo; Estrogen therapy should not be used for prevention of cardiovascular disease.
  • PROBABLE DEMENTIA: The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. Estrogen therapy should not be used for prevention of dementia.
  • In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens and other dosage forms of estrogens.
  • Estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

CONTRAINDICATIONS:
  • Undiagnosed abnormal uterine bleeding
  • Known, suspected or history of breast cancer
  • Known or suspected estrogen-dependent neoplasia
  • Active deep vein thrombosis, pulmonary embolism, or history of these conditions
  • Active arterial thromboembolic disease (e.g., stroke, myocardial infarction) or a history of these conditions
  • Hypersensitivity (e.g., anaphylactic reaction or angioedema) to estrogens, bazedoxifene or any product ingredients
  • Known liver impairment or disease
  • Known protein C, protein S or antithrombin deficiency or other known thrombophilic disorders
  • Known or suspected pregnancy
  • Nursing mothers

Safety and efficacy have not been established in premenopausal women or women greater than 75 years.

Consult WARNINGS section for dosing related precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • May take without regard to meals
  • Swallow tablets whole

Missed Dose: If a dose is missed, it should be taken as soon as remembered, but two doses should not be taken at the same time

Storage requirements:
  • Tablets should not be removed from blisters
  • After opening foil pouch, product must be used within 60 days

General:
  • When prescribed for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be considered.
  • When prescribed for the prevention of postmenopausal osteoporosis, supplemental calcium and/or vitamin D should be added if daily intake is inadequate.

Monitoring: Thyroid function in women on thyroid replacement

Patient advice:
  • Patients should be instructed to read US FDA-approved patient labeling (Patient Information).
  • Patients should understand that they should not take additional estrogen products while taking this drug.
  • Patients should be instructed not to place tablets in pill boxes or pill organizers; they should record date that the blister package is opened in the space provided on the package and use within 2 months.
  • Patients should be instructed to report any unusual vaginal bleeding or signs or symptoms related to venous thrombosis or thromboembolic events to their health care provider promptly.
  • Patients should be instructed to get their daily recommended amount of calcium and vitamin D.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by